查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1734895

2032 年链球菌咽头炎治疗市场预测：按治疗类型、给药途径、疾病类型、通路、诊断方法、最终用户和地区进行的全球分析

Strep Throat Treatment Market Forecasts to 2032 - Global Analysis By Treatment Type, Route of Administration, Disease Type, Distribution Channel, Diagnosis Method, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2025 年全球链球菌性咽头炎治疗市场价值为 22.6 亿美元，预计到 2032 年将达到 38.8 亿美元，预测期内复合年增长率为 8.0%。

链球菌咽头炎的治疗主要包括使用抗生素清除引起感染的化脓性链球菌。常用的抗生素包括阿莫西林和青霉素，但过敏患者也可以使用头孢氨芐或阿奇霉素治疗。早期抗生素治疗可以减轻症状的严重程度和持续时间，避免风湿热等併发症，并降低感染传播给他人的风险。此外，支持性治疗有助于控制发烧、发炎和喉咙痛等症状。这包括休息、补充水分以及服用对乙酰胺酚和Ibuprofen等非处方止痛药。

根据美国疾病管制与预防中心 ( 美国) 的建议，抗生素治疗 A 型链球菌 (GAS)咽头炎对于缩短症状持续时间、预防併发症和限制感染至关重要。青霉素或阿莫西林因其有效性、窄频谱和低成本而被推荐作为一线治疗药物。

链球菌感染疾病盛行率不断上升

化脓性链球菌，又称为A类溶血性链球菌或GAS，是链球菌性咽喉炎的病原体。链球菌性咽喉炎是一种常见的细菌感染疾病，主要影响5至15岁的儿童。美国疾病管制与预防中心估计，美国每年有数百万例轻度链球菌性咽头炎感染疾病和1.1万至2.4万例侵袭性GAS病例。在全球范围内，医疗保健服务可能有限的中低收入国家的负担更为沉重。此外，由于这种持续存在的流行病，支持性治疗、诊断和抗生素市场持续蓬勃发展。

抗生素过度处方和误诊

链球菌性咽头炎治疗市场面临的一个主要障碍是咽喉痛的常见误诊。儘管许多咽头炎是由病毒而非细菌引起的，但医生经常在未进行充分检测的情况下开立抗生素处方。这种误诊不仅会导致不必要的用药，还会加剧抗生素抗药性，进而降低治疗效果。根据美国疾病管制与预防中心 (CDC) 统计，美国门诊高达 30% 的抗生素处方是不必要的。此外，这种过度处方带来的监管压力和更严格的处方指南可能会透过减少滥用抗生素的销售，间接抑制市场扩张。

家用快速诊断试剂盒的开发

家用快速感染疾病诊断套件的开发，源自于人们对自我检测和分散式医疗服务的需求。与家用 COVID-19 检测和妊娠检测类似，数位健康和​​分子诊断技术的发展使消费者能够使用市售套件进行感染疾病自我检测。此外，这些技术进步有助于更早发现和治疗，从而减轻临床基础设施的压力，尤其是在偏远和资源匮乏的地区。企业可以透过投资易于使用、准确且价格合理的诊断解决方案，来利用这消费者主导的市场扩张。

学名药竞争和市场饱和

咽头炎的治疗主要依靠少数几种已使用数十年的知名抗生素。其中许多药物，例如阿莫西林和青霉素，都存在更便宜的学名药。这导致了激烈的价格竞争和狭窄的净利率，抑制了该领域的医药投资和创新。此外，缺乏独特的产品也阻碍了市场扩张，导致人们高度依赖批量采购协议和公开竞标，而这些方式并不总是有利可图。

COVID-19的影响：

新冠疫情对链球菌性咽头炎药物市场造成了衝击。一方面，佩戴口罩、保持社交距离和改善卫生习惯等预防措施的广泛实施，显着减少了链球菌性咽喉炎和其他常见呼吸道感染疾病的感染疾病。另一方面，疫情也加速了远端医疗和家用诊断设备的普及，为感染疾病的诊断和处方治疗开闢了新的途径。此外，随着大众对感染疾病和抗生素管理意识的提高，处方实践和就医行为也发生了变化，链球菌性咽喉炎的管理和治疗方法也与时俱进。

口服药物市场预计将成为预测期内最大的市场

预计口服製剂领域将在预测期内占据最大的市场占有率。口服抗生素，尤其是青霉素和阿莫西林，因其疗效确切、使用方便、价格实惠且患者依从性高，是链球菌咽头炎的一线治疗药物。在门诊治疗方面，大多数成人和儿童患者更倾向于口服药物，而不是注射剂或外用药物。锭剂、胶囊和混悬液等口服製剂易于获取，无需医护人员监督，非常适合在资源有限的环境中使用。此外，它们的广泛获取和易用性也是其在链球菌咽头炎治疗领域广受欢迎的原因。

预计急性链球菌感染疾病部分在预测期内将以最高的复合年增长率成长。

预计急性链球菌感染疾病领域将在预测期内达到最高成长率。 A组溶血性链球菌感染疾病的全球发生率不断上升，尤其是在最容易感染急性链球菌感染疾病的儿童和青少年群体中，这推动了该领域的成长。扩大就地检验，并提高对早期诊断和适当抗生素治疗的认识，有助于及时发现和治疗急性感染疾病。此外，为了避免风湿热和链球菌感染后肾丝球肾炎等併发症，医护人员优先治疗急性病例，增加了治疗需求。

占比最大的地区：

预计北美将在预测期内占据最大的市场占有率。这得归功于其强大的医疗保健体系、对感染疾病的高度认知以及便捷的诊疗服务。该地区链球菌感染疾病的盛行率很高，尤其是在学龄儿童中，这导致对快速诊断检测和抗生素的需求持续增长。机构和政府对定期健康检查、抗生素管理和早期诊断的重视进一步推动了市场扩张。此外，顶级製药公司的入驻以及持续的研发也正在提高治疗的可用性和创新性。

复合年增长率最高的地区：

预计亚太地区将在预测期内实现最高的复合年增长率。这得益于该地区人口众多且不断增长、感染疾病知识水平不断提高以及医疗保健服务的便利性。在中国、印度和东南亚等国家，感染疾病和其他呼吸道感染疾病呈现上升趋势，尤其是在年轻人和老年人口。由于政府采取措施改善初级医疗保健、提高抗生素可近性以及扩大农村地区的医疗覆盖率，市场正在扩大。此外，由于对远端医疗、诊断基础设施和公共卫生计划的投资不断增加，该地区的市场正在迅速扩张。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 全面分析其他市场参与者（最多 3 家公司）
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家市场进行估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 应用分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球链球菌咽头炎治疗市场（依治疗类型）

  • 抗生素
    • 阿莫西林
    • 青霉素
  • 止痛药
  • 益生菌疗法
  • 草本/天然疗法
  • 其他类型的治疗

6. 全球链球菌咽头炎治疗市场（依给药途径）

  • 口服
  • 话题
  • 注射

7. 全球链球菌咽头炎治疗市场（依疾病型态）

  • 急性链球菌咽头炎
  • 咽头炎
  • 扁桃腺炎
  • 喉炎
  • 其他类型的疾病

8. 全球链球菌咽头炎治疗市场（依通路）

  • 医院药房
  • 零售药局
  • 网路药局

9. 全球链球菌咽头炎治疗市场（依诊断方法）

  • 抗体检测
  • 身体检查
  • 咽喉培养
  • 快速抗原检测试验（RADT）

第 10 章。全球链球菌咽头炎治疗市场（依最终用户划分）

  • 医院
  • 专科诊所
  • 诊断实验室
  • 其他最终用户

第 11 章。全球链球菌咽头炎治疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司概况

  • Bayer AG
  • GSK plc（GlaxoSmithKline）
  • Abbott Laboratories
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Novartis AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • Melinta Therapeutics
  • Dr. Reddy's Laboratories Ltd.
  • Azurity Pharmaceuticals, Inc.
  • Mylan NV（Viatris）
  • Sandoz
  • Cipla Ltd.
  • Sun Pharmaceutical Industries Ltd.
Product Code: SMRC29532

According to Stratistics MRC, the Global Strep Throat Treatment Market is accounted for $2.26 billion in 2025 and is expected to reach $3.88 billion by 2032 growing at a CAGR of 8.0% during the forecast period. Strep throat treatment primarily involves the use of antibiotics to eliminate the Streptococcus pyogenes bacteria responsible for the infection. Commonly prescribed antibiotics include amoxicillin or penicillin, but patients with allergies may also be treated with cephalexin or azithromycin. The severity and duration of symptoms can be lessened, complications like rheumatic fever can be avoided, and the chance of infecting others is decreased with early antibiotic treatment. Moreover, supportive care can help manage symptoms like fever, inflammation, and sore throat. It includes rest, hydration, and over-the-counter pain relievers like acetaminophen or ibuprofen.

According to the Centers for Disease Control and Prevention (CDC), antibiotic treatment for group A streptococcal (GAS) pharyngitis is essential to reduce symptom duration, prevent complications, and limit transmission. Penicillin or amoxicillin is the recommended first-line therapy due to their efficacy, narrow spectrum, and low cost.

Market Dynamics:

Driver:

Growing streptococcal infection prevalence

Streptococcus pyogenes, also known as Group A Streptococcus or GAS, is the causative agent of strep throat, a common bacterial infection that primarily affects children between the ages of 5 and 15. The CDC estimates that millions of mild cases, such as strep throat, and between 11,000 and 24,000 cases of invasive GAS disease occur each year in the United States. In low- and middle-income nations where access to healthcare may be restricted, the burden is even greater globally. Additionally, the market for supportive therapies, diagnostics, and antibiotics is constantly active due to this enduring prevalence.

Restraint:

Over prescription and incorrect diagnosis of antibiotics

A major barrier to the market for strep throat treatments is the common misdiagnosis of sore throats. Antibiotics are often prescribed without adequate testing, even though many sore throats are viral rather than bacterial. The effectiveness of treatment is compromised because this not only results in needless drug use but also fuels antibiotic resistance. In outpatient settings in the United States, up to 30% of antibiotic prescriptions are unnecessary, according to the CDC. Furthermore, regulatory pressure and tighter prescription guidelines brought about by this over prescription can indirectly stifle market expansion by reducing the sale of indiscriminate antibiotics.

Opportunity:

Developments in at-home and quick diagnostics

The development of quick and at-home strep throat diagnostic kits has been prompted by the move toward self-testing and decentralization of care. Similar to home COVID-19 or pregnancy tests, consumers can now self-test for streptococcal infections using over-the-counter kits owing to developments in digital health and molecular diagnostics. Moreover, these developments facilitate early detection and treatment and lessen the strain on clinical infrastructure, particularly in isolated or resource-constrained locations. Businesses can take advantage of this expanding consumer-driven market by investing in diagnostic solutions that are easy to use, precise, and reasonably priced.

Threat:

Generic competition and market saturation

A small number of well-known antibiotics that have been used for decades dominate the market for strep throat treatments. There are inexpensive generic versions of many of these medications, including amoxicillin and penicillin. This deters significant pharmaceutical investment and innovation in this field by resulting in fierce price competition and narrow profit margins. Additionally, lack of unique products can impede market expansion and increase reliance on bulk purchasing agreements or public-sector tenders, which aren't always profitable.

Covid-19 Impact:

The COVID-19 pandemic affected the market for strep throat treatments. On the one hand, strep throat and other common respiratory infections have become much less common as a result of the widespread adoption of preventive measures like mask wearing, social distancing, and better hygiene. The pandemic, however, hastened the uptake of telemedicine and at-home diagnostic instruments, opening up new avenues for the diagnosis and prescription of strep throat remedies. Furthermore, the management and treatment of strep throat has also changed over time as a result of changes in prescribing practices and healthcare-seeking behaviour brought about by heightened public awareness of infectious diseases and antimicrobial stewardship.

The oral segment is expected to be the largest during the forecast period

The oral segment is expected to account for the largest market share during the forecast period. Due to their demonstrated effectiveness, simplicity of use, affordability, and high patient compliance, oral antibiotics-especially penicillin and amoxicillin-are the first-line treatment for strep throat. When it comes to outpatient treatment, the majority of patients-adults and children alike-prefer oral medications over inject able or topical ones. Since oral dosage forms like tablets, capsules, and suspensions are widely accessible and don't need a medical professional's supervision, they can be used even in environments with limited resources. Moreover, their widespread availability and ease of use help explain why they are so popular in the world of strep throat remedies.

The acute strep throat segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the acute strep throat segment is predicted to witness the highest growth rate. The rising incidence of Group A Streptococcus infections worldwide, especially in children and adolescents who are most susceptible to acute strep throat, is what is driving this segment's growth. The expansion of point-of-care testing and growing knowledge of early diagnosis and appropriate antibiotic treatment facilitate quicker acute infection detection and management. Additionally, in order to avoid complications like rheumatic fever and post-streptococcal glomerulonephritis, medical professionals are giving priority to acute cases, which raises the need for treatment.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by a strong healthcare system, a high level of infectious disease awareness, and easy access to services for diagnosis and treatment. The high incidence of strep throat in the area, particularly in school-age children, contributes to the ongoing need for quick diagnostic tests and antibiotics. Market expansion is further supported by a strong institutional and governmental emphasis on routine health examinations, antibiotic stewardship, and early diagnosis. Furthermore, the availability and innovation of treatments are improved by the presence of top pharmaceutical companies and continuous research and development.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR because of its sizable and expanding population, increased knowledge of infectious diseases, and easier access to medical care. Strep throat and other respiratory tract infections are on the rise in countries like China, India, and Southeast Asia, especially in young people and the elderly. The market is expanding as a result of government efforts to improve primary healthcare, as well as increased access to antibiotics and healthcare outreach in rural areas. Additionally, the region's market is expanding quickly due to rising investments in telehealth, diagnostic infrastructure, and public health initiatives.

Key players in the market

Some of the key players in Strep Throat Treatment Market include Bayer AG, GSK plc (GlaxoSmithKline), Abbott Laboratories, Merck & Co., Inc., Pfizer Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd, Melinta Therapeutics, Dr. Reddy's Laboratories Ltd., Azurity Pharmaceuticals, Inc., Mylan N.V. (Viatris), Sandoz, Cipla Ltd. and Sun Pharmaceutical Industries Ltd.

Key Developments:

In March 2025, Bayer and Suzhou Puhe BioPharma Co.,Ltd announced that they have entered into a global license agreement for Puhe BioPharma's oral, small molecule PRMT5 inhibitor that selectively targets MTAP-deleted tumors. Under the agreement, Bayer obtains an exclusive worldwide license to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor.

In March 2025, Merck and Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that the companies have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 clinical trial in China. Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop manufacture and commercialize HRS-5346 worldwide, excluding Greater China region.

In December 2024, Abbott Laboratories and DexCom they have reached an agreement to settle all patent disputes between them related to continuous glucose monitoring devices. The agreement will dismiss all pending cases in courts and patent offices worldwide, along with a provision preventing legal action between the companies for patent and appearance disputes for the next 10 years.

Treatment Types Covered:

  • Antibiotics
  • Pain Relievers
  • Probiotic Therapies
  • Herbal/Natural Remedies
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Topical
  • Injectable

Disease Types Covered:

  • Acute Strep Throat
  • Pharyngitis
  • Tonsillitis
  • Laryngitis
  • Other Disease Types

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Diagnosis Methods Covered:

  • Antibody Test
  • Physical Examination
  • Throat Culture
  • Rapid Antigen Detection Tests (RADTs)

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Diagnostic Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Strep Throat Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Antibiotics
    • 5.2.1 Amoxicillin
    • 5.2.2 Penicillin
  • 5.3 Pain Relievers
  • 5.4 Probiotic Therapies
  • 5.5 Herbal/Natural Remedies
  • 5.6 Other Treatment Types

6 Global Strep Throat Treatment Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Topical
  • 6.4 Injectable

7 Global Strep Throat Treatment Market, By Disease Type

  • 7.1 Introduction
  • 7.2 Acute Strep Throat
  • 7.3 Pharyngitis
  • 7.4 Tonsillitis
  • 7.5 Laryngitis
  • 7.6 Other Disease Types

8 Global Strep Throat Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacy
  • 8.3 Retail Pharmacy
  • 8.4 Online Pharmacy

9 Global Strep Throat Treatment Market, By Diagnosis Method

  • 9.1 Introduction
  • 9.2 Antibody Test
  • 9.3 Physical Examination
  • 9.4 Throat Culture
  • 9.5 Rapid Antigen Detection Tests (RADTs)

10 Global Strep Throat Treatment Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Specialty Clinics
  • 10.4 Diagnostic Laboratories
  • 10.5 Other End Users

11 Global Strep Throat Treatment Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Bayer AG
  • 13.2 GSK plc (GlaxoSmithKline)
  • 13.3 Abbott Laboratories
  • 13.4 Merck & Co., Inc.
  • 13.5 Pfizer Inc.
  • 13.6 Novartis AG
  • 13.7 Sanofi
  • 13.8 Teva Pharmaceutical Industries Ltd
  • 13.9 Melinta Therapeutics
  • 13.10 Dr. Reddy's Laboratories Ltd.
  • 13.11 Azurity Pharmaceuticals, Inc.
  • 13.12 Mylan N.V. (Viatris)
  • 13.13 Sandoz
  • 13.14 Cipla Ltd.
  • 13.15 Sun Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Strep Throat Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Strep Throat Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 3 Global Strep Throat Treatment Market Outlook, By Antibiotics (2024-2032) ($MN)
  • Table 4 Global Strep Throat Treatment Market Outlook, By Amoxicillin (2024-2032) ($MN)
  • Table 5 Global Strep Throat Treatment Market Outlook, By Penicillin (2024-2032) ($MN)
  • Table 6 Global Strep Throat Treatment Market Outlook, By Pain Relievers (2024-2032) ($MN)
  • Table 7 Global Strep Throat Treatment Market Outlook, By Probiotic Therapies (2024-2032) ($MN)
  • Table 8 Global Strep Throat Treatment Market Outlook, By Herbal/Natural Remedies (2024-2032) ($MN)
  • Table 9 Global Strep Throat Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 10 Global Strep Throat Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 11 Global Strep Throat Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 12 Global Strep Throat Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 13 Global Strep Throat Treatment Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 14 Global Strep Throat Treatment Market Outlook, By Disease Type (2024-2032) ($MN)
  • Table 15 Global Strep Throat Treatment Market Outlook, By Acute Strep Throat (2024-2032) ($MN)
  • Table 16 Global Strep Throat Treatment Market Outlook, By Pharyngitis (2024-2032) ($MN)
  • Table 17 Global Strep Throat Treatment Market Outlook, By Tonsillitis (2024-2032) ($MN)
  • Table 18 Global Strep Throat Treatment Market Outlook, By Laryngitis (2024-2032) ($MN)
  • Table 19 Global Strep Throat Treatment Market Outlook, By Other Disease Types (2024-2032) ($MN)
  • Table 20 Global Strep Throat Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 21 Global Strep Throat Treatment Market Outlook, By Hospital Pharmacy (2024-2032) ($MN)
  • Table 22 Global Strep Throat Treatment Market Outlook, By Retail Pharmacy (2024-2032) ($MN)
  • Table 23 Global Strep Throat Treatment Market Outlook, By Online Pharmacy (2024-2032) ($MN)
  • Table 24 Global Strep Throat Treatment Market Outlook, By Diagnosis Method (2024-2032) ($MN)
  • Table 25 Global Strep Throat Treatment Market Outlook, By Antibody Test (2024-2032) ($MN)
  • Table 26 Global Strep Throat Treatment Market Outlook, By Physical Examination (2024-2032) ($MN)
  • Table 27 Global Strep Throat Treatment Market Outlook, By Throat Culture (2024-2032) ($MN)
  • Table 28 Global Strep Throat Treatment Market Outlook, By Rapid Antigen Detection Tests (RADTs) (2024-2032) ($MN)
  • Table 29 Global Strep Throat Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 30 Global Strep Throat Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 31 Global Strep Throat Treatment Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 32 Global Strep Throat Treatment Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 33 Global Strep Throat Treatment Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.